Bromphen DM and Pseudoephedrine Dosing
For Bromphen DM (brompheniramine/dextromethorphan combination), use the FDA-approved dosing: adults and children ≥12 years take 10 mL every 4 hours; children 6-11 years take 5 mL every 4 hours; children 2-5 years take 2.5 mL every 4 hours; maximum 6 doses per 24 hours. 1
Adult Dosing
Bromphen DM
- Adults and children ≥12 years: 10 mL (2 teaspoonfuls) every 4 hours
- Maximum: 6 doses in 24 hours 1
Pseudoephedrine (when used separately)
- Adults and children ≥12 years: 2 tablets (60 mg each) every 4-6 hours
- Maximum: 8 tablets (480 mg) in 24 hours 2
Pediatric Dosing
Bromphen DM
- Children 6 to <12 years: 5 mL (1 teaspoonful) every 4 hours
- Children 2 to <6 years: 2.5 mL (½ teaspoonful) every 4 hours
- Infants 6 months to <2 years: Dosage must be established by physician
- Maximum: 6 doses in 24 hours for all age groups 1
Pseudoephedrine (when used separately)
- Children 6-11 years: 1 tablet (30 mg) every 4-6 hours
- Maximum: 4 tablets (120 mg) in 24 hours
- Children <6 years: Do not use 2
Critical Safety Considerations
Serotonin syndrome risk: The combination of dextromethorphan (in Bromphen DM) with SSRIs like sertraline can precipitate serotonin syndrome even at therapeutic doses. Watch for confusion, dilated pupils, myoclonus, and speech difficulties. If these occur, immediately discontinue both medications. 3
Pseudoephedrine cardiovascular effects: Expect heart rate increases of 2-4 beats per minute above baseline. Monitor for tachycardia, hypertension, and cardiac arrhythmias, particularly in patients with pre-existing cardiovascular disease. 4
Sedation profile: Brompheniramine (first-generation antihistamine) causes significantly more drowsiness than non-sedating alternatives. This sedation is dose-dependent and cumulative with multiple doses. 5
Pharmacokinetic Considerations
The elimination half-life of pseudoephedrine in children (3.1 ± 0.5 hours) is significantly shorter than in adults, explaining the need for more frequent dosing intervals in pediatric populations. 6 Weight-adjusted clearance remains independent of age in children 4-11 years, supporting consistent mg/kg dosing across this age range. 7
Efficacy Context
For cough suppression: Dextromethorphan demonstrates efficacy in chronic bronchitis but has limited benefit for acute upper respiratory infection cough. The generally recommended dosage is likely subtherapeutic; maximum cough reflex suppression occurs at 60 mg with prolonged effect. 8
For nasal congestion: Pseudoephedrine 60 mg provides statistically significant reduction in nasal airway resistance compared to placebo after both single and multiple doses, with effects measurable by objective rhinomanometry. 4
Antihistamine component: Chlorpheniramine (similar to brompheniramine) exhibits higher efficacy for rhinorrhea and general cold symptoms compared to pseudoephedrine alone, though with increased sedation. 9
Overdose Management
Toxic manifestations: Dextromethorphan overdose causes drowsiness, ataxia, nystagmus, and seizures. Brompheniramine overdose ranges from CNS depression to stimulation (especially in children) with anticholinergic effects. Pseudoephedrine toxicity presents as CNS stimulation, tachycardia, hypertension, and arrhythmias. 1
Treatment approach: If alert and presenting within 6 hours, induce emesis with aspiration precautions. Naloxone 0.005 mg/kg IV may reverse dextromethorphan-induced CNS depression. Use short-acting IV barbiturates for CNS hyperactivity or seizures. Manage hypertension and tachycardia appropriately with supportive care. 1